Sedentary Lifestyle Will Drive Global Diabetes Therapies Market to $69 Billion by 2023 - by The Business Research Company
LONDON, July 18, 2019 /PRNewswire/ -- The global diabetes therapies market, valued at $50.8 billion in 2018, will grow to more than $69 billion by 2023 at an annual growth rate of about 6%. This growth in the forecast period can be attributed to the ageing population and increasing prevalence of sedentary lifestyles leading to obesity, thus increasing the risks of diabetes. Changing lifestyles are leading to a higher prevalence of diabetes; type II diabetes in particular. Long working hours, less physical activity, and unhealthy eating and drinking habits are the major causes of diabetes. According to a study conducted in 2018, there was a high prevalence of diabetes in people with sedentary lifestyles. Additionally, people suffering from obesity are up to 80 times more likely to develop type 2 diabetes. According to a World Health Organization (WHO) report, 74% of men and 64% of women in the UK, for instance, are expected to be overweight by 2030. These factors are expected to increase the patient pool of diabetes, thereby driving the diabetes therapies market during the forecast period.
Read More On The Business Research Company's Diabetes Therapies Market Report:
https://www.thebusinessresearchcompany.com/report/diabetes-therapies-market
Also,
Place a DIRECT PURCHASE of Complete Report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2311
Top Diabetes Therapies Opportunities Are in The Injectables Segment
The Business Research Company suggests that 68% of all diabetes drugs and therapies $ sales gains by 2023 will come from injectables, adding up to almost $12 billion in annual sales. To take advantage of these opportunities, pharma manufacturers should use the strategies suggested by The Business Research Company's analysis of the diabetic therapy market trends, including the development of new drugs for diabetes-associated comorbidities, and investing in expanding manufacturing operations. For instance, University at Buffalo spinoff Transira Therapeutics LLC is developing an injectable, hormone-based drug to support the treatment of type 2 diabetes patients. Sanofi S.A., a competitor in the diabetic therapies market, spent EUR 5.5 billion ($6.2 billion) for late stage product development in 2017.
REQUEST A SAMPLE of this Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2311&type=smp
Increasing Access To Injectables In Developing Countries
The diabetes drugs market can be segmented into the oral drugs market and injectable drugs market. Oral drugs are mainly used in the treatment of type 2 and gestational diabetes, to control blood glucose levels. Injectable therapies include insulin administered through the use of insulin pens and insulin syringes. Insulin pens and syringes are used for injecting insulin into the body, mainly for the treatment of type 1 diabetes. In some cases, type 2 and gestational diabetes patients also require insulin injectables.
The injectables drugs segment was the largest segment in the global diabetic therapies market in 2018, with around 63% of the global total. This large share in the market was due to the prices of injectables being higher than for oral drugs. This segment is expected to grow at the highest forecast annual growth rate of around 7% to 2023. Major factors for this growth include increasing access to injectables in developing and some underdeveloped countries. The oral drugs segment is expected to be the slower growing segment, at an annual growth rate of about 5.5%.
Innovations In Diabetes Therapies Research And Development
Novel techniques relating to diabetes therapies research and development include gene editing, and identification of microbial strains for the treatment of diabetes. For example, in December 2016, researchers at Lund University Diabetes Centre in Sweden, worked on CRISPR, a genome modification tool. This resulted in the turning off of one of the genes responsible for causing diabetes. This effectively decreased beta cell death and increased insulin production in the pancreas.
Here Is A List Of Similar Reports By The Business Research Company:
The World's Most Comprehensive Database:
The Business Research Company's Global Market Model analyses all the above data and more. It is the world's most comprehensive database of integrated market information. This market intelligence platform covers various macroeconomic indicators and metrics across 56 geographies and 24 industries.
Interested to know about The Business Research Company?
The Business Research Company has published over 300 industry reports, covering over 2400 market segments and 56 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact Information:
The Business Research Company
G. Nitin
Email: info@tbrc.info
Europe: +44-207-1930-708
Asia: +91-8897263534
Americas: +1-315-623-0293
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_Info
Logo: https://mma.prnewswire.com/media/947575/The_Business_Research_Company_Logo.jpg
